🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Meningococcal B Vaccine in Patients with Asplenia

RecruitingPhase 2Ages 18 Years - 60 YearsAllMedical University of Vienna
NCT06025487 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate. Meningococcal bacteria can cause such infections and serogroup B is the dominant meningococcal subtype in Europe. Therefore, vaccination for risk populations like patients without a spleen is a pressing matter. Considering the effectiveness of the meningococcal serogroup B vaccine, data for this high-at-risk population is currently lacking. The aim of this study is to evaluate the meningococcal B vaccine (BEXSERO®) in patients without a spleen compared to a healthy control group. A total of 40 patients and 40 healthy persons will receive a two-dose schedule of BEXSERO® with a one-month interval between doses. The effectiveness of the vaccine will be determined by measuring antibodies against different meningococcal strains in the bl

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: For asplenic patients: * asplenia due to splenectomy or functional asplenia * 18 to 60 years of age * if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study * providing written informed consent For healthy controls: * 18 to 60 years of age * if female: have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study * providing written informed consent Exclusion Criteria: For asplenic patients: * pregnant or lactating * febrile illness within last two weeks prior to enrolment * allergic reactions to vaccination in past * chemotherapy with Rituximab within last six months or during study period * more than 20mg prednisone per day within last four weeks prior or at the time of enrolment * previous vaccination against meningococcal serogroup B For healthy controls: * pregnant or lactating * febrile illness within last two weeks prior to enrolment * allergic reactions to vaccination in past * any immunosuppressive condition or medication * previous vaccination against meningococcal serogroup B
💊

What it tests

  • Bexsero
📍

Where

1 site
Medical University Vienna
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy